Protocol No.: D8531C00002

CAMBRIA-1: A Phase III, Open-Label, Randomised Study to Assess the Efficacy and Safety of Extended Therapy with Camizestrant (AZD9833, a Next Generation, Oral Selective Estrogen Receptor Degrader) versus Standard Endocrine Therapy (Aromatase Inhibitor or Tamoxifen) in Patients with ER+/HER2- Early Breast Cancer and an Intermediate or High Risk of Recurrence Who Have Completed Definitive Locoregional Therapy and at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Without Disease Recurrence
Principal Investigator
Kurian, Sobha
Phase
III
Age Group
Adult
Applicable Disease Site
Breast Cancer
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Emily Hawkins, BSN
Research Nurse
Phone: +1 304-293-7375

View on ClinicalTrials.gov